argenx to discontinue Phase 3 UNITY Sjögren’s efgartigimod study
argenx said it will discontinue its Phase 3 UNITY study of subcutaneous efgartigimod in adults with moderate-to-severe Sjögren’s disease following an interim analysis.
argenx said it will discontinue its Phase 3 UNITY study of subcutaneous efgartigimod in adults with moderate-to-severe Sjögren’s disease following an interim analysis.